Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Oct 25 | 2023Novartis Q3 ’23 Earnings; Counterfeit Ozempic Hospitalizes Patients in Austria; NexImmune Extends Partnership with Yale and JDRFPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Oct 23 | 2023Insulet Receives 510(k) Clearance for O5 iPhone App; Viking Completes Enrollment for Ph2 GLP-1/GIP RA Studyin ObesityPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 20 | 2023Lilly Hires CordenPharma to Make Mounjaro; Diamyd Booster ResultsPurchase Blast
$599
Posted in: Other, SGLT2i Oct 19 | 2023Novo Partners with GE Healthcare for T2DM/Obesity; Cytokinetics’ Cardiac Myosin Inhibitor Programs Update; New Ph3 Dapa+Zibotentan Combination Trial in CKD and High ProteinuriaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Oct 18 | 2023Abbott Q3 ’23 Earnings; Tzield PROTECT Data at ISPAD 2023; Viking GLP-1/GIP RA Ph1 Data at ObesityWeekPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, Other, SGLT2i Oct 17 | 2023Novo to Displace Metformin as 1L T2DM Treatment?; Zealand Presents Amylin Analog Data at ObesityWeek; JNJ Q3 ‘23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, Other Oct 16 | 2023SURMOUNT-3 Presented at ObesityWeek; Novo Adds to Its CKD Pipeline; Carmot Presents T2DM/Obesity Results; Better Therapeutics Launches AspyreRx for T2DMPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Oct 13 | 2023Novo Raises 2023 Guidance; Glucotrack’s Implantable CGM Preclinical ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Oct 11 | 2023Lilly Initiates Tirzepatide Obesity Trial in Adolescents; Survodutide CVOT Observed; FDA Creates New Digital Health Advisory Committee; Better Therapeutics Announces AspyreRx Subgroup Topline Results; Virta Partners with Navitus for T2DM and ObesityPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Oct 10 | 2023Novo's FLOW Stops Early; Akero Misses in Ph2b NASH Study; Insulet Wins Preliminary Injunction Against EOFlow; Biocon Recieves Another CRL; Inpefa Receives Preferred Formulary Status with ESI; Carmot Oral GLP-1RA Ph1 DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other, SGLT2i Oct 09 | 2023Best Buy to Sell Dexcom G7; Gan & Lee Submits Bs-aspart and Bs-lispro MAAs; October CHMP Agenda; Tom Garner Joins Lexicon as SVP and CCO; Dario Partners with a Top Five Employee Benefits Consulting Firm; Senseonics and Ascensia Launch Eversense E3 Advertising CampaignPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Oct 05 | 2023EASD Key Press Releases (Oct 5)Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Oct 05 | 2023EASD Key Press Releases (Oct 4)Purchase Blast$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 03 | 2023EASD 2023 Key Press Releases (Oct 03)Purchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Oct 02 | 2023EASD 2023 Key Press Releases (Oct 02)Purchase Blast
$599
Posted in: GLP-1RA, Other Sep 29 | 2023Structure Announces Positive Topline Results from Ph1b Oral GLP-1RA Study; Better Therapeutics Completes Enrollment of AspyreRX Clinical Program in T2DM; Madrigal Commences $500M Public OfferingPurchase Blast
$599
Posted in: DPP-IVi, GLP-1RA, Other, SGLT2i Sep 28 | 2023Ozempic Label Update; AZ, BMS, Merck, and BI to Participate in Medicare Price Negotiations; FDA and Health Canada Clear Expansion Portion of Biomea’s Ph2 Oral Menin Inhibitor Trial in T2DMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Sep 27 | 2023Rockley Photonics Progresses Non-Invasive, Optical Blood Glucose Monitoring; Intercept to be Acquired by Alfasigma; EMA to Discuss GLP-1RA-Associated Aspiration Risks; Kallyope Initiates Ph2 trial of Oral Obesity and T2DM TreatmentPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Sep 26 | 2023Novo Partners with Valo Health for CVD and Evotec for Cardiometabolic Drug Discovery Accelerator; Zucara Doses First Patient in Ph2a ZONE Trial; Merck Initiates Efinopegdutide Study in Hepatic Impairment; Senseonics Completes Adult Arm of ENHANCE Pivotal Study; NeuroBo Posts Ph2 DA-1241 Trial in NASH to CT.govPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Sep 25 | 2023FDA Approves Jardiance for Adults with CKD; Abbott Completes Bigfoot Acquisition; Insulet Publishes “Market Opportunity & Impact of GLP-1s” Presentation; Lilly initiates Ph3 H2H Orforglipron vs. Semaglutide and New Ph3b Tirzepatide Max Dose Study in ObesityPurchase Blast